The children studied developed virus-fighting antibodies similar to the levels vaccinated adults received from a full dose.
According to a recent news release from Moderna, studies have shown that children ages 6 to 11 have strong immune responses to the company’s kid-size COVID-19 vaccination, which offered young children half the normal dose given to adults with positive results. Moderna reported Monday that then half-dose given of their vaccine is safe and appears to work in young children ages 6 to 11. Moderna has not gotten approval to offer its shot to children yet but is currently studying the results from lower doses on volunteers in hopes to expand vaccines to children soon. Moderna tested two child-sized doses a month apart, and found the children developed virus-fighting antibodies similar to the levels vaccinated adults received from a full dose, Moderna said in a release. Moderna hopes to join its rival, Pfizer, in offering vaccines to younger children soon.
